Fact or myth: Is decentralization the future in clinical trials?

Cover Image

“70% of potential participants live more than two hours from trial sites, so decentralization broadens trial access to reach a larger number and potentially more diverse pool of patients,” writes McKinsey and Company.

This quote teases a few advantages of decentralized clinical trials (DCTs), which accommodate the changing landscape of clinical trials—influenced by patient centricity, new wearable technology, and increasingly personalized medicines.

Hop into minute 6 of this webinar to understand the ins and outs of DCTs, including:

  1. The benefits of DCTs
  2. DCT types, considerations, best practices, & impact
  3. Loftware Prisym 360 overview
  4. And more
Vendor:
Loftware
Premiered:
Apr 4, 2024
Format:
HTML
Type:
Webcast
Already a Bitpipe member? Log in here

Download this Webcast!